Publications by authors named "R Wolk"
Am J Clin Dermatol
October 2024
Article Synopsis
- The ALLEGRO study assessed the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), focusing on patient-reported hair loss outcomes.
- Patients aged 12 and older with significant scalp hair loss participated in a 48-week trial comparing different dosages of ritlecitinib to a placebo.
- Results showed that 5-36% of ritlecitinib patients reported improved hair loss after 24 weeks, which correlated with positive changes in emotional symptoms and activity limitations, indicating the treatment's beneficial effects.
Br J Dermatol
October 2024
Article Synopsis
- The ALLEGRO studies show that ritlecitinib is effective and well-tolerated for treating alopecia areata in patients aged 12 and older for up to 24 months.
- Results indicate significant improvement in hair regrowth, with a marked increase in patients achieving favorable Severity of Alopecia Tool (SALT) scores at both 12 and 24 months.
- The safety profile of ritlecitinib remains consistent with previous studies, confirming its long-term tolerability for users.
J Am Acad Dermatol
October 2024
Article Synopsis
- This study investigates the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), over 48 weeks in patients with varying responses by Week 24.
- Results showed that over 85% of patients who had good responses at Week 24 maintained their improvement, while some nonresponders also began to show better results by Week 48.
- The study had a small sample size, but it concludes that ritlecitinib can lead to sustained hair regrowth in many patients with AA.
Article Synopsis
- A post-hoc analysis of the ALLEGRO study assessed the effects of ritlecitinib, an oral JAK inhibitor, in treating patients aged 12 and older with alopecia totalis (AT) and alopecia universalis (AU) over 48 weeks.
- Out of 718 patients, those treated with ritlecitinib showed significantly higher hair regrowth response rates compared to the placebo group, improving from week 24 to week 48.
- Ritlecitinib was well tolerated, demonstrating clinical efficacy and an acceptable safety profile for patients with both AT and AU.
Dermatol Ther (Heidelb)
October 2024
Article Synopsis
- The ALLEGRO study showed that ritlecitinib, a JAK3/TEC inhibitor, is effective and safe for treating alopecia areata in patients aged 12 and older with significant scalp hair loss.
- A post hoc analysis examined how previous alopecia treatments affected treatment outcomes using the Severity of Alopecia Tool (SALT) in patients taking ritlecitinib.
- Results indicated that prior use of intralesional corticosteroids improved short-term outcomes, while systemic immunosuppressants worsened them, but overall, previous treatment history did not significantly influence long-term responses to ritlecitinib.
